Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Explore this paper's citation graph
Summary
Bisphosphonate therapies, including zoledronic acid (ZA), have emerged as a promising means of reducing bone loss associated with antiaromatase therapy and Forthcoming results from all these trials should determine whether ZA could be used to improve bone heath in women undergoing adjuvant therapy with AAAs for breast cancer.
- Type
- review
- Published
- 2006-02-01
- Cited by
- 37
- References
- 39
- OpenAlex
- https://openalex.org/W2103526339
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:22790975
Keywords
Medicine, Letrozole, Tamoxifen, Breast cancer, Anastrozole
References
- Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome
- Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
- What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及
- Osteoporosis due to cancer treatment: pathogenesis and management.
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
- Skeletal health in postmenopausal survivors of early breast cancer
- Skeletal complications of malignancy
- A high incidence of vertebral fracture in women with breast cancer
- P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer
- The ATAC (‘rimidex’, amoxifen, lone or in ombination) trial in postmenopausal women with early breast cancer—Updated efficacy results based on a median follow-up of 47 months
- The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months
- Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone
- Osteoporosis in women with breast cancer
- Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy
- Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study)
- Long-term implications of bone loss in breast cancer.
- Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
- American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Cited by
- Optimal management of metastatic bone disease.
- Aromatase Inhibitor-Associated Bone Loss
- Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab.
- Hormonapplikation und gynäkologische Tumortherapie
- Aromatase Inhibitors and Osteoporosis-Risk, Prevention and Treatment Review
- Bisphosphonates and breast cancer incidence and recurrence
- Management of breast cancer in elderly patients
- Skeletal effects of drugs to treat cancer.
- Managing Aromatase Inhibitor-Associated Bone Loss in Breast Cancer
- Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
- Endocrine therapy for breast cancer: an overview.
- Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
- The use of bisphosphonates in cancer patients
- Reducing the risk of bone loss associated with breast cancer treatment.
- Zoledronic acid: clinical potential beyond the prevention of skeletal complications in patients with cancer
- Adverse bone effects during pharmacological breast cancer therapy
- Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
- Aromatase inhibitor and bone.
- Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.
- Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Related papers
- Sequential Treatment with Exemestane and Non-Steroidal Aromatase Inhibitors in Advanced Breast Cancer
- Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
- An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane
- Cardiovascular Profiles of Aromatase Inhibitors May Be Different, but Clinical Relevance Unknown
- [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
- Optimal Treatment Strategies in Hormone-Responsive Early Breast Cancer: The Role of Aromatase Inhibitors
- Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
- Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
- Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors